Related Experiment Video
Updated: Mar 13, 2026

Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting
Andrea Zanichelli1, Hilary J Longhurst2, Marcus Maurer3
1Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, ASST Fatebenefratelli Sacco, Milan, Italy.
Insights
Approximately 44% of patients with hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) experience misdiagnosis, often as allergic angioedema or appendicitis. This leads to significant delays in proper treatment for C1-INH-HAE.
Area of Science:
- Immunology
- Genetics
- Rare Diseases
Background:
- Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling episodes.
- C1-INH-HAE often presents with abdominal pain, skin, and upper airway swelling.
- Delayed diagnosis of C1-INH-HAE can result in inadequate treatment and unnecessary medical procedures.
Purpose of the Study:
- To investigate the prevalence and patterns of misdiagnosis in patients with C1-INH-HAE.
- To analyze the impact of misdiagnosis on the diagnostic timeline for C1-INH-HAE.
Main Methods:
- Data were collected from the Icatibant Outcome Survey (IOS), an observational study.
- Patients with C1-INH-HAE (type I or II) reported prior misdiagnoses before their confirmed diagnosis.
- Misdiagnosis rates were analyzed based on demographics, C1-INH-HAE type, and family history.
Main Results:
- Of 418 patients, 185 (44.3%) reported at least one prior misdiagnosis.
- Common misdiagnoses included allergic angioedema (103/185) and appendicitis (50/185).
- Patients with a family history of C1-INH-HAE had significantly lower misdiagnosis rates (41.7% vs 65.5%).
- Misdiagnosed patients faced a median diagnostic delay of 13.3 years compared to 1.7 years for correctly diagnosed patients.
Conclusions:
- Nearly half of C1-INH-HAE patients experience misdiagnosis, frequently as allergic conditions or appendicitis.
- Misdiagnosis significantly prolongs the time to correct diagnosis and effective treatment for C1-INH-HAE.
- Early recognition and diagnosis are crucial for timely management and improved patient outcomes.
Background:
Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) causes swelling in the skin and upper airways and pain in the abdomen because of mucosal swelling. C1-INH-HAE is frequently misdiagnosed, leading to delays in diagnosis, inadequate treatment, and unnecessary procedures.
Objective:
To evaluate the history of misdiagnosis in patients participating in the Icatibant Outcome Survey (IOS).
Methods:
The IOS is an observational study in which safety and effectiveness of icatibant have been evaluated since 2009. As part of the IOS, patients record any misdiagnoses received before being diagnosed as having C1-INH-HAE.
Results:
In January 2016, a total of 418 of 633 IOS patients with C1-INH-HAE type I or II had provided misdiagnosis data. Of these, 185 of 418 (44.3%) received 1 or more prior misdiagnoses. The most common misdiagnoses were allergic angioedema (103 of 185) and appendicitis (50 of 185). A variety of other misdiagnoses were reported, including a substantial number of gastrointestinal disorders (excluding appendicitis). Misdiagnosis rates were similar between males (41.1%) and females (46.5%) and between C1-INH-HAE type I (43.7%) and type II (51.6%). Patients with family members diagnosed as having C1-INH-HAE were significantly less likely to be misdiagnosed than patients without a family history (140 of 366 [41.7%] vs 38 of 58 [65.5%], respectively; P = .001). Patients with a prior misdiagnosis had longer median delay to C1-INH-HAE diagnosis (13.3 years) than patients without (1.7 years; P < .001).
Conclusion:
From this large database, approximately 50% of patients with C1-INH-HAE type I or II have previously had their conditions misdiagnosed, most commonly as allergic angioedema or appendicitis. Misdiagnosis results in marked delays in receiving the correct diagnosis, during which time patients cannot access effective, lifesaving treatment.
Trial Registration:
ClinicalTrials.gov: NCT01034969.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Angina III: Clinical Manifestations and Assessment
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Errors occurring during blood pressure monitoring
Several factors...